Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and BioMarin Pharmaceutical (BMRN)
IQVIA Holdings Initiated at Outperform by RBC Capital
IQVIA Hldgs Analyst Ratings
RBC Capital Initiates IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $275
JP Morgan Maintains Overweight on IQVIA Hldgs, Raises Price Target to $288
IQVIA Hldgs Analyst Ratings
Argus Research Maintains IQVIA Holdings(IQV.US) With Buy Rating
Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $312
Stifel Nicolaus Remains a Buy on IQVIA Holdings (IQV)
Jefferies Downgrades IQVIA to Hold, Cites Subdued Market Outlook
Jefferies Downgrades IQVIA Holdings(IQV.US) to Hold Rating, Cuts Target Price to $242
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $242 to $275
Jefferies Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $242 From $266
IQVIA Holdings: A Strong Buy on Robust R&D and Tech Growth Prospects
IQVIA Holdings Outperforms With Strong Q2 Results and Positive Growth Outlook: Cherny Maintains Buy Rating
HSBC Adjusts Price Target on IQVIA to $290 From $280
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $251 to $300
IQVIA Holdings Price Target Raised to $251.00/Share From $235.00 by Baird
IQVIA Hldgs Analyst Ratings